Vaccine Biosafety, Virus & QC Testing | HyQure

Vaccine Development and Biosafety Testing

Seed-lot, virus-bank, adventitious-agent, microbial, viral-safety, and release-support testing for vaccine programs.

Request a Quote Contact a Scientific Project Manager

Modality > Biologics > Vaccine Development Testing

Program Overview

Vaccine programs require controlled testing around seed or virus banks, adventitious-agent risk, microbial safety, process residues where relevant, and release-facing documentation. HyQure supports vaccine-related workflows through virus testing, microbial and mycoplasma pathways, endotoxin support, viral clearance or inactivation validation where applicable, and sponsor-facing reporting aligned to product type and development stage.

Why HyQure - Advantages

Adventitious-agent and virus testing

In vitro virus testing, in vivo virus testing where relevant, and broad biosafety control for seed or substrate materials form the core vaccine-testing story.
Seed-lot and virus-bank support

Use virus-bank, cell-substrate, and supporting documentation language instead of unsupported efficacy or immunogenicity claims.
Microbial safety and release support

Mycoplasma, sterility, endotoxin support, and lot-release workflows should be the central quality story.
Regulatory-aware package design

Study outputs are described as phase-appropriate and regulatory-facing, with WHO-oriented language used only when framed as submission support rather than approval outcomes.

Supported Vaccine Testing Scope

Seed / virus bank qualification

Testing strategies for master or working virus banks, seed lots, and related substrate materials.
Adventitious-agent and virus testing

In vitro virus testing, in vivo virus-testing pathways where justified, and contaminant-risk control for vaccine manufacturing materials.
Microbiological testing

Mycoplasma, sterility, endotoxin support, rapid microbiology where confirmed, and related quality-control workflows.
Viral clearance / inactivation and release support

Viral clearance or inactivation validation where applicable to the process, together with release-support documentation and QC summaries.

Sample Types and Deliverables

Sample types

Seed stocks, virus banks, production substrates, bulk harvest materials, intermediates, and final release-support samples depending on platform.

Key deliverables

Qualification reports, virus-test summaries, microbial test reports, release-support documentation, and quality-facing technical packages.

Scope alignment

Non-routine vaccine analytics should be confirmed through technical scoping before they are presented as part of the supported package..

Logistics

Where sample transport is required, handling, customs, and cold-chain expectations should be aligned with the program-specific shipment process.